Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery.
Molecular biology and genomic sciences are revealing the early biological signatures for many diseases. In response, the Molecular Imaging community is rapidly developing contrast agents to visualize the nascent pathological changes and to concomitantly deliver treatment directly to the site of disease. The evaluation, development and use of these new agents require a complementary understanding of contrast chemistry and imaging techniques. The fundamental issues surrounding magnetic contrast agent development, rational drug delivery, MR molecular imaging, and their interdependence are elucidated.
Lanza
Gregory M
GM
Division of Cardiology, Campus Box 8086, Washington University Medical School, 600 S. Euclid Ave, Saint Louis, MO 63110, USA. greg@cvu.wustl.edu
Winter
Patrick
P
Caruthers
Shelton
S
Schmeider
Anne
A
Crowder
Kathy
K
Morawski
Anne
A
Zhang
Huiying
H
Scott
Michael J
MJ
Wickline
Samuel A
SA
D000818:Animals; D001704:Biopolymers / Q000032:analysis / Q000378:metabolism*; D003287:Contrast Media; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008280:Magnetics; D008967:Molecular Biology / Q000379:methods; D015336:Molecular Probe Techniques; D015335:Molecular Probes; D043942:Nanotubes / Q000737:chemistry / Q000648:ultrastructure
D001704:Biopolymers; D003287:Contrast Media; D015335:Molecular Probes